Difference between revisions of "Categories of SUIT protocols"
Beno Marija (talk | contribs) |
|||
Line 4: | Line 4: | ||
'''Categories of SUIT protocols''' group [[MitoPedia: SUIT |SUIT protocols]] according to all substrate types involved in a protocol (F, N, S, Gp), independent of the sequence of titrations of substrates and inhibitors which define the [[pathway control state]]s. The [[N-pathway control |N-type substrates]] are listed in parentheses, independent of the sequence of titrations. ROX states may or may not be included in a SUIT protocol, which does not change its category. Similarly, the [[CIV]] assay may or may not be added at the end of a SUIT protocol, without effect on the category of a SUIT protocol. | '''Categories of SUIT protocols''' group [[MitoPedia: SUIT |SUIT protocols]] according to all substrate types involved in a protocol (F, N, S, Gp), independent of the sequence of titrations of substrates and inhibitors which define the [[pathway control state]]s. The [[N-pathway control |N-type substrates]] are listed in parentheses, independent of the sequence of titrations. ROX states may or may not be included in a SUIT protocol, which does not change its category. Similarly, the [[CIV]] assay may or may not be added at the end of a SUIT protocol, without effect on the category of a SUIT protocol. | ||
* '''F''' - | * '''F''' - ET-pathway-level 5: [[FADH2 |FADH<sub>2</sub>]]-linked substrates (FAO) with obligatory support by the N-linked pathway. | ||
* '''N''' - | * '''N''' - ET-pathway-level 4: [[NADH]]-linked substrates (CI-linked). | ||
* '''S''' - | * '''S''' - ET-pathway-level 3: [[Succinate]] (CII-linked). | ||
* '''Gp''' - | * '''Gp''' - ET-pathway-level 3: [[Glycerophosphate]] (CGpDH-linked). | ||
Β» [[#Categorization of SUIT protocols: ETS pathway control states |'''MiPNet article''']] | Β» [[#Categorization of SUIT protocols: ETS pathway control states |'''MiPNet article''']] | ||
Line 16: | Line 16: | ||
}} | }} | ||
__TOC__ | __TOC__ | ||
= Categories of SUIT protocols and | = Categories of SUIT protocols and ET-pathway control states = | ||
{{Publication | {{Publication | ||
|title=Gnaiger E (2017) Categories of SUIT protocols and ETS pathway control states. MiPNet 2017-03-12; original 2016-03-20; edited 2016-08-21. | |title=Gnaiger E (2017) Categories of SUIT protocols and ETS pathway control states. MiPNet 2017-03-12; original 2016-03-20; edited 2016-08-21. | ||
Line 34: | Line 34: | ||
== Towards a library of SUIT protocols == | == Towards a library of SUIT protocols == | ||
:::: At the present stage of development of the [[MitoPedia:_SUIT#Library_of_SUIT_protocols |Library of SUIT protocols]] as part of the [[MitoFit Quality Control System]], the substrate types linked to five | :::: At the present stage of development of the [[MitoPedia:_SUIT#Library_of_SUIT_protocols |Library of SUIT protocols]] as part of the [[MitoFit Quality Control System]], the substrate types linked to five ET-pathway types are considered. | ||
::::* '''F-junction''' on the pathway level of converging FADH<sub>2</sub>- and NADH-linked dehydrogenases, including beta-oxidationthe and segments of the TCA cycle. | ::::* '''F-junction''' on the pathway level of converging FADH<sub>2</sub>- and NADH-linked dehydrogenases, including beta-oxidationthe and segments of the TCA cycle. | ||
::::* '''N-junction''' on the pathway level of NADH-linked dehydrogenases, including the TCA cycle. | ::::* '''N-junction''' on the pathway level of NADH-linked dehydrogenases, including the TCA cycle. | ||
Line 43: | Line 43: | ||
== Single pathway type == | == Single pathway type == | ||
=== | === ET-pathway-level 1: CIV === | ||
[[File:SUIT-catg CIV.jpg|200px]] | [[File:SUIT-catg CIV.jpg|200px]] | ||
=== | === ET-pathway-level 3: S, CII-pathway to Q === | ||
[[File:SUIT-catg S.jpg|200px]] | [[File:SUIT-catg S.jpg|200px]] | ||
=== | === ET-pathway-level 3: Gp, CGpDH-pathway to Q === | ||
[[File:SUIT-catg Gp.jpg|200px]] | [[File:SUIT-catg Gp.jpg|200px]] | ||
=== | === ET-pathway-level 4: N, N-junction or CI-pathway to Q === | ||
[[File:SUIT-catg N.jpg|200px]] | [[File:SUIT-catg N.jpg|200px]] | ||
=== | === ET-pathway-level 5: F, FAO, F-junction, CETF- supported by CI-pathway to Q === | ||
[[File:SUIT-catg F.jpg|200px]] | [[File:SUIT-catg F.jpg|200px]] | ||
== Multiple | == Multiple ET-pathway with FNSGp == | ||
[[File: SUIT-catg_FNSGpCIV.jpg|200px]] | [[File: SUIT-catg_FNSGpCIV.jpg|200px]] | ||
== Multiple | == Multiple ET pathways with NS == | ||
=== NS === | === NS === | ||
Line 78: | Line 78: | ||
== Multiple | == Multiple ET pathways with N (without S) == | ||
=== FN === | === FN === | ||
Line 90: | Line 90: | ||
== Multiple | == Multiple ET pathways without N == | ||
:::: Addition of malate alone (M without P or G) is not considered as substrate type N. However, high mt-malic enzyme activity requires a change of this concept, when M alone represents an | :::: Addition of malate alone (M without P or G) is not considered as substrate type N. However, high mt-malic enzyme activity requires a change of this concept, when M alone represents an ET-pathway ccompetent substrate state. Low concentration of M may be used to support FAO, whereas a higher concentration of M may be required for N-junction respiratory capacity to override FAO capacity; this needs corresponding kinetic analyses ([[SUIT test protocols]]). | ||
=== FS === | === FS === |
Revision as of 13:45, 20 October 2017
Description
Categories of SUIT protocols group SUIT protocols according to all substrate types involved in a protocol (F, N, S, Gp), independent of the sequence of titrations of substrates and inhibitors which define the pathway control states. The N-type substrates are listed in parentheses, independent of the sequence of titrations. ROX states may or may not be included in a SUIT protocol, which does not change its category. Similarly, the CIV assay may or may not be added at the end of a SUIT protocol, without effect on the category of a SUIT protocol.
- F - ET-pathway-level 5: FADH2-linked substrates (FAO) with obligatory support by the N-linked pathway.
- N - ET-pathway-level 4: NADH-linked substrates (CI-linked).
- S - ET-pathway-level 3: Succinate (CII-linked).
- Gp - ET-pathway-level 3: Glycerophosphate (CGpDH-linked).
Abbreviation: SUIT-catg
Reference: MiPNet21.06 SUIT RP
MitoPedia concepts:
MiP concept,
SUIT concept
Categories of SUIT protocols and ET-pathway control states
Gnaiger E (2017) Categories of SUIT protocols and ETS pathway control states. MiPNet 2017-03-12; original 2016-03-20; edited 2016-08-21. |
Abstract: The complexity of SUIT protocols is primarily determined by the large number of pathway control states and fuel substrates involved, compared to only three well defined coupling control states. Whereas the SUIT protocol names specify all sequential steps in a SUIT protocol, the categories of SUIT protocols reduce this diversity to a list of substrate types involved.
β’ O2k-Network Lab: AT Innsbruck OROBOROS
Labels: MiParea: Instruments;methods
Pathway: F, N, S, Gp, CIV, NS, Other combinations, ROX
HRR: Theory
Towards a library of SUIT protocols
- At the present stage of development of the Library of SUIT protocols as part of the MitoFit Quality Control System, the substrate types linked to five ET-pathway types are considered.
- F-junction on the pathway level of converging FADH2- and NADH-linked dehydrogenases, including beta-oxidationthe and segments of the TCA cycle.
- N-junction on the pathway level of NADH-linked dehydrogenases, including the TCA cycle.
- Q-junction on the pathway level of electron transfer complexes converging at the Q-junction (S and Gp).
- Tm on the single step level of cytochrome c oxidase (CIV), the terminal step in the aerobic electron transfer system. Tm can be included or excluded at the end of a SUIT protocol. To simplify the categorization, Tm is not considered in this system of SUIT protocols.
- At the present stage of development of the Library of SUIT protocols as part of the MitoFit Quality Control System, the substrate types linked to five ET-pathway types are considered.
Single pathway type
ET-pathway-level 1: CIV
ET-pathway-level 3: S, CII-pathway to Q
ET-pathway-level 3: Gp, CGpDH-pathway to Q
ET-pathway-level 4: N, N-junction or CI-pathway to Q
ET-pathway-level 5: F, FAO, F-junction, CETF- supported by CI-pathway to Q
Multiple ET-pathway with FNSGp
Multiple ET pathways with NS
NS
FNS
NSGp
FNSGp
Multiple ET pathways with N (without S)
FN
NGp
FNGp
Multiple ET pathways without N
- Addition of malate alone (M without P or G) is not considered as substrate type N. However, high mt-malic enzyme activity requires a change of this concept, when M alone represents an ET-pathway ccompetent substrate state. Low concentration of M may be used to support FAO, whereas a higher concentration of M may be required for N-junction respiratory capacity to override FAO capacity; this needs corresponding kinetic analyses (SUIT test protocols).